EnWave Successfully Enriches nutraDRIED(TM) Fruit Products with B-galactosidase Enzyme

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 19, 2013) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or the "Company") announced today that it has successfully used its proprietary Radiant Energy Vacuum ("REV™") dehydration technology to enrich nutraDRIED™ fruit products with the enzyme B-galactosidase; an enzyme responsible for breaking down lactose, a sugar found mainly in milk and other dairy products. The enzyme retained 90% of its activity after several months of storage at room temperature within the fruit's natural structure at 10% moisture. This result validates the potential use of nutraDRIED™ food products as delivery vehicles for nutraceuticals and bioactive materials.

The nutraDRIED™ fruit enriched with B-galactosidase is designed to be used as an ingredient in cereal mixes, targeting lactose intolerant individuals. The enzyme gradually releases from the fruit, breaking down the lactose before the milk enters the large intestine, thus avoiding the negative side effects caused by lactose intolerance. Approximately 20% of Canadians and around 30 million American adults have some degree of lactose intolerance diagnosed by the age of 20. To the Company's knowledge, this is the first time dried fruit has been used as a carrier for B-galactosidase.

"The ability to enrich food products with enzymes via our proprietary process could open up many new unique commercial opportunities," stated Dr. Tim Durance, Chairman & Co-CEO. "More specifically, enriching nutraDRIED™ fruit with B-galactosidase could provide lactose intolerant people with the ability to consume cereal and milk without having to take separate tablets to break down the lactose."

About EnWave

EnWave Corporation is a Vancouver-based industrial technology company developing commercial applications for its proprietary Radiant Energy Vacuum (REV™) dehydration technology. The company licensed REV™ technology to Milne Fruit Products Inc in 2011, its first major U.S. customer, to support a launch of healthy berry snacks and powders across most major markets in North America. More recently, EnWave licensed REV™ technology to one of its Tier 1 multinational collaborators from the list below. In addition, EnWave has entered into a wide range of research and collaboration agreements with an expanding list of multinational companies, including Nestlé, Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray Cranberries, Hormel, Bonduelle, Cherry Central, Sun-Maid Growers, Gay Lea and Merck. EnWave is introducing REV™ as a new dehydration standard in the food and biological material sectors: potentially faster and cheaper than freeze drying, with better end product quality than air drying or spray drying.

EnWave currently has six REV™ platforms: commercial-scale nutraREV^® and MIVAP^® are used in the food industry to dry fruits, vegetables, meat, herbs and seafood quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour. The Company is also developing powderREV™ for bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes; quantaREV™ for continuous, high-volume low-temperature drying of pastes, gels, liquids, or particulates; and bioREV™ and freezeREV™ as new methods to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.